News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

H. Lundbeck A/S Enters Into License Agreement With Kyowa Hakko Kirin For A2a Antagonists For Parkinson's and Other Indications


10/6/2010 8:19:40 AM

Reuters -- H. Lundbeck A/S (Lundbeck) today announced that it has signed an agreement with Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Lundbeck will also have the right to further select compounds as either back-up or additional indication compounds. Adenosine A2a antagonists have potential applications in a wide range of therapeutic indications, including Parkinson's disease. Kyowa Hakko Kirin will retain rights to develop and commercialise the compounds in Japan and the Asian region.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES